ALSO NOTED: Daiichi Sankyo files supplemental NDA; BioSante launches Phase III trial; and much more...

> Daiichi Sankyo has filed a supplemental NDA with the FDA, looking for approval to use WelChol to improve glycemic control. Report

> Antares Pharma's development partner, BioSante Pharmaceuticals, has initiated a Phase III safety and efficacy trial of Antares' transdermal testosterone gel for the treatment of FSD. Release

> pSivida has been released from a loan covenant. Release

> Biomira has begun enrolling patients for a Phase II pancreatic cancer study. Release

And Finally… Dr. Gilbert Welch says that part of what afflicts Americans is an epidemic of diagnoses. Editorial

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.